From 2013 to 2015, keeping other factors constant, chemotherapy use was estimated to decline from 34.5% (95% confidence interval [CI] = 30.8% to 38.3%) to 21.3% (95% CI=19.0% to 23.7%, P < .001). Sequencing results were confirmed by in-house developed full high resolution DNA melting (HRM) analysis. She is also a clinically active oncologist, treating patients diagnosed with breast cancer. In preclinical studies, statins inhibit multiple cancer-associated pathways in both hormone receptor (HR)-negative and HR-positive cell lines. A., Lipson, J. Kurian, A. W., Griffith, K. A., Hamilton, A. S., Ward, K. C., Morrow, M. n., Katz, S. J., Jagsi, R. n. Recent Trends in Chemotherapy Use and Oncologists' Treatment Recommendations for Early-Stage Breast Cancer. Breast cancer is a common manifestation of an underlying genetic susceptibility to cancer, and 5% to 10% of all breast cancers are associated with a germline mutation in a known risk allele. The HRD-LOH assay was able to identify patients with sporadic triple-negative breast cancer lacking a BRCA1/2 mutation, but with an elevated HRD-LOH score, who achieved a favorable pathologic response. Clarke, C. A., Hubbell, E., Kurian, A. W., Colditz, G. A., Hartman, A. R., Gomez, S. L. Abstract P5-03-02: Cancer risks associated with pathogenic variants in the ataxia telangiectasia mutated (ATM) gen. Hall, M., Larson, K., Bernhisel, R., Hughes, E., Rosenthal, E., Singh, N., Lancaster, J. M., Kurian, A. W. Pathogenic Variants in Breast Cancer Susceptibility Genes in Older Women-Reply. View details for DOI 10.1007/s11764-019-00820-7. For women aged 20-39years, 5-year risk performed better than lifetime risk from birth. Joint estimation of Single Nucleotide Polymorphism (SNP) effects in models could improve predictive performance over standard approaches of PRS construction. We searched key electronic databases to identify studies evaluating hereditary cancer cascade testing. The results of this case series suggest a reduced risk of breast cancer associated with RRSO in the immediate 5 years after surgery in women carrying BRCA1 and BRCA2 pathogenic variants, and a longer-term association with cumulative breast cancer risk in women carrying BRCA1 pathogenic variants. However, it may also reflect racial/ethnic differences in the distributions of personal and family histories among breast cancer cases in the Northern California population. Cause-specific proportional hazards models estimated SPLC risk. B., Strauch, K., Styrkarsdottir, U., Swerdlow, A. J., Tanaka, T., Teras, L. R., Teumer, A., orsteinsdottir, U., Timpson, N. J., Toniolo, D., Traglia, M., Troester, M. A., Truong, T., Tyrrell, J., Uitterlinden, A. G., Ulivi, S., Vachon, C. M., Vitart, V., Vlker, U., Vollenweider, P., Vlzke, H., Wang, Q., Wareham, N. J., Weinberg, C. R., Weir, D. R., Wilcox, A. N., van Dijk, K. W., Willemsen, G., Wilson, J. F., Wolffenbuttel, B. H., Wolk, A., Wood, A. R., Zhao, W., Zygmunt, M., Chen, Z., Li, L., Franke, L., Burgess, S., Deelen, P., Pers, T. H., Grndahl, M. L., Andersen, C. Y., Pujol, A., Lopez-Contreras, A. J., Daniel, J. AMCs reported greater challenges navigating insurance issues, particularly prior authorization. not yet known whether letrozole is more effective than a placebo in treating patients with
Overall survival and time to next treatment were evaluated. [5][6] He also pursued an MBA from Stanford Graduate School of Business. We assessed trends in NAC use and surgical procedures in California from January 1, 1998 to December 31, 2012 using statewide population-based cancer registry data.A total of 236,797 females diagnosed with stage I-III BC were studied. Clinician estimates of systemic recurrence risk were provided for patient sub-groups with DCIS and with low-, intermediate-, and high-risk invasive disease. The authors incorporated records from the population-based California Cancer Registry and then linked EMR-California Cancer Registry data sets of Community and University patients.The authors initially identified 8210 University patients and 5770 Community patients; linked data sets revealed a 16% patient overlap, yielding 12,109 unique patients. Sexual health concerns represent one of the most frequently experienced and longest-lasting effects of breast cancer treatment, but research suggests that service providers rarely discuss sexual health with their patients. Patients' attending surgeons were surveyed about genetic testing and results management. Kurian, A. W., Canchola, A. J., Gomez, S. L. Prevalence of Lynch syndrome in women with mismatch repair-deficient ovarian cancer. Cox regression was used to assess associations of common germline variants with 15-year and 5-year breast cancer-specific survival. survival by adding iniparib (BSI-201/SAR240550) to the combination of gemcitabine/carboplatin
Thompson, C. A., Kurian, A. W., Luft, H. S. Diabetes and Other Comorbidities in Breast Cancer Survival by Race/Ethnicity: The California Breast Cancer Survivorship Consortium (CBCSC). We conducted cross-cancer GWAS and transcriptome-wide association studies (TWAS) to discover novel cancer susceptibility loci. This antimicrobial-mortality association is independent of changes in neutrophil count, is unrelated to disease severity, and is sustained through year three following diagnosis, suggesting antimicrobial exposure negatively impacts TNBC survival. The study was performed in the Mohn Cancer Research Laboratory (Bergen, Norway) between 2019 and 2022.Associations between BRCA1 methylation and incident TNBC and incident HGSOC were analyzed by Cox proportional hazards regression.Of 2478 cases and controls in the TNBC group and 3493 cases and controls in the HGSOC group, respectively, 7 (0.3%) and 3 (0.1%) were American Indian or Alaska Native, 46 (1.9%) and 30 (0.9%) were Asian, 1 (0.04%) and 1 (0.03%) was Native Hawaiian or Pacific Islander, 326 (13.2%) and 125 (3.6%) were Black or African, 56 (2.3%) and 116 (3.3%) were Hispanic, 2046 (82.6%) and 3257 (93.2%) were White, and 35 (1.4%) and 35 (1.0%) were multiracial. In BCAC, increasing PRS313 was associated with lower grade, hormone receptor-positive status, and smaller tumor size. The daughter of two prominent academics, Diana Chapman Walsh the former President of Wellesley College and Chris Walsh, a renowned Harvard biochemist - Allison was destined by genetics and environment, it seems, to become the exceptional scholar and clinician-scientist who now directs the Stanford Women's Clinical Cancer Genetics Program. (2-7) In the Women's Health Initiative (WHI) Observational Study (OS), women with NMSC history at baseline were more likely to report history of another cancer (Odds ratio [OR] = 2.3, 95% CI = 2.18 -2.44. View details for Web of Science ID 000306969100011, View details for PubMedCentralID PMC3640371. Although two thirds of patients were tested before surgical treatment, patients without private insurance more often experienced delays. A., Teo, S. H., Teras, L. R., Toland, A. E., Tollenaar, R. A., Torres, D., Torres-Meja, G., Troester, M. A., Truong, T., Vachon, C. M., Vijai, J., Weinberg, C. R., Wendt, C., Winqvist, R., Wolk, A., Wu, A. H., Yamaji, T., Yang, X. R., Yu, J. C., Zheng, W., Ziogas, A., Ziv, E., Dunning, A. M., Easton, D. F., Hemingway, H., Hamann, U., Kuchenbaecker, K. B. Jayasekera, J., Lowry, K. P., Yeh, J. M., Schwartz, M. D., Wernli, K. J., Isaacs, C., Kurian, A. W., Stout, N. K. A pilot study to increase cascade genetic testing in families with hereditary cancer syndromes. These common alleles were associated with clinical extremes of ANM; women in the top 1% of genetic susceptibility have an equivalent risk of premature ovarian insufficiency to those carrying monogenic FMR1 premutations3. In this review, we compiled data from 11 participating Asian countries (Bangladesh, Mainland China, Hong Kong SAR, Indonesia, Japan, Korea, Malaysia, Philippines, Singapore, Thailand and Vietnam), and from ethnic Asians residing in Canada and the USA. This clinical effect was not restricted to a few of the tested genes because most identified genes could change clinical management for some patients.In a clinically representative cohort, multigene panel testing for HBOC risk assessment yielded findings likely to change clinical management for substantially more patients than does BRCA1/2 testing alone. Interestingly, many of these genes, like BRCA1/2, are involved in homologous recombination DNA double-stranded repair. These results may inform clinical decision-making about ET, and reassure patients who have bothersome symptoms on AIs that they are unlikely to develop worse comorbidities if they switch to tamoxifen. African American PV carriers had similarly elevated risks of CBC as non-Hispanic White PV carriers. Compared with breast-conserving surgery with radiation (10-year mortality, 16.8% [95% CI, 16.6%-17.1%]), unilateral mastectomy was associated with higher all-cause mortality (hazard ratio [HR], 1.35 [95% CI, 1.32-1.39]; 10-year mortality, 20.1% [95% CI, 19.9%-20.4%]). This two-cohort, open-label, multicenter, phase 2 study will assess the safety and efficacy
Comparison of the Prevalence of Pathogenic Variants in Cancer Susceptibility Genes in Black Women and Non-Hispanic White Women With Breast Cancer in the United States. Among African American women, BC-specific mortality was higher among those treated at non-accredited hospitals (HR 1.57, CI 1.21-2.04) and those from lower SES neighborhoods (HR 1.48, CI 1.16-1.88) compared to NHW women without these characteristics. The changes in breast cancer incidence across the pandemic did not vary by demographic factors. Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer . Family cancer history is an important component of genetic testing guidelines that estimate which patients with breast cancer are most likely to carry a germline pathogenic variant (PV). Breast oncology precision medicine: Genomic testing and treatment at the population level. Multi-step processing, including deep-learning-based segmentation, revealed variability in the composition of tumor-immune populations across individuals, reconciled by overall immune infiltration and enriched co-occurrence of immune subpopulations and checkpoint expression. Using descriptive statistics, payer characteristics were compared between adopters and nonadopters and between pre-NCD and post-NCD adopters. Our model maintains a Markov belief about the effectiveness of the different therapies and updates it as therapies are administered and tumor images are observed, reflecting tumor response. For more information, please contact Pei-Jen Chang, 650-725-0866. Better risk communication by clinicians may translate to better risk comprehension among patients and to improvements in QoL. Incorporation of the S4 PRS in risk prediction models for ovarian cancer may have clinical utility in ovarian cancer prevention programs. tumor. To guide decisions informed by multiple health outcomes, we provide an online tool for joint use by patients with their physicians (http://brcatool.stanford.edu). By contrast, VUS results were more frequent among nonwhites, with potential significance for the impact of MGS testing by race/ethnicity.GENETICS in MEDICINE advance online publication, 27 July 2017; doi:10.1038/gim.2017.96. Multivariable-adjusted Cox proportional hazards models were used to investigate the relationship between statin use and cancer survival.Compared with never-users, current statin use was associated with significantly lower risk of cancer death (hazard ratio (HR), 0.78; 95% confidence interval (CI), 0.71-0.86, P<0.001) and all-cause mortality (HR, 0.80; 95% CI, 0.74-0.88). B., Tomlinson, I., Fitzgerald, R., Gharahkhani, P., Gockel, I., Jankowski, J., Macgregor, S., Schumacher, J., Barnholtz-Sloan, J., Bondy, M. L., Houlston, R. S., Jenkins, R. B., Melin, B., Wrensch, M., Brennan, P., Christiani, D., Johansson, M., Mckay, J., Aldrich, M. C., Amos, C. I., Landi, M. T., Tardon, A., Bishop, D. T., Demenais, F., Goldstein, A. M., Iles, M. M., Kanetsky, P. A., Law, M. H., Amundadottir, L. T., Stolzenberg-Solomon, R., Wolpin, B. M., Klein, A., Petersen, G., Risch, H., Chanock, S. J., Purdue, M. P., Scelo, G., Pharoah, P., Kar, S., Hung, R. J., Pasaniuc, B., Kraft, P. Cascade Genetic Risk Education and Testing in Families With Hereditary Cancer Syndromes: A Pilot Study. Cancer 2018;000:000-000. Symptoms and survivorship needs differences between "good sleepers" and "bad sleepers" in survivors of breast and gynecologic cancers. B., Taplin, S. H., Gomez, S. L. Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer. Guidelines focus on syndromes associated with an increased risk of breast and/or ovarian cancer and are intended to assist with clinical and shared decision-making. The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian provide recommendations for genetic testing and counseling and risk assessment and management for hereditary cancer syndromes. Future research should identify the aspects of ACS program hospitals that are associated with higher survival and evaluate strategies by which to enhance access to and use of high-quality hospitals, particularly among African American women. Stanford is currently not accepting patients for this trial. The risk of CBC was estimated for PV carriers in each gene compared with women without PVs in a multivariate proportional hazard regression analysis accounting for the competing risk of death and adjusting for patient and tumor characteristics. The practice of genetic testing for hereditary breast and/or ovarian cancer (HBOC) is rapidly evolving owing to the recent introduction of multigene panels. Unique associations include an inverse relation of serous cancer risk to body mass index, a positive relation of mucinous cancer risk to cigarette smoking, and a weakly positive relation of endometrioid cancer risk to body mass index. Adjusted time to next treatment hazard ratio was 0.89 (95% confidence interval: 0.62-1.29). Li-Fraumeni syndrome is a highly penetrant cancer syndrome associated with a high lifetime risk for cancer, including soft tissue sarcomas, osteosarcomas, premenopausal breast cancer, colon cancer, gastric cancer, adrenocortical carcinoma, and brain tumors. To test for the association with breast cancer risk, we carried out follow-up genotyping in 90,916 cases and 89,893 controls from the Breast Cancer Association Consortium. Absolute excess risks were higher after BCT and ULM (5.0 and 13.6 more cases, respectively) compared with BLM (28.6 fewer cases). Results were similar for breast cancer-specific survival, except that African Americans and non-Hispanic Whites living in high-SES neighborhoods had similar survival.Strategies to address the underlying factors that may influence treatment intensity and adherence, such as comorbidities and logistical barriers, should be targeted at low-SES non-Hispanic White and all African American patients. In case-control analysis, CDH1 and BRCA2 PVs were associated with high risks of ILC (odds ratio [OR] > 4) and CHEK2, ATM, and PALB2 PVs were associated with moderate (OR = 2-4) risks. Results were most sensitive to variations in our assumptions about the magnitude and duration of breast cancer risk reduction due to prophylactic oophorectomy.Life expectancy gains depend on the type of BRCA mutation and age at interventions. Solutions. Rising Bilateral Mastectomy Rates Among Neoadjuvant Chemotherapy Recipients in California From 1998 to 2012. Chemotherapy Decisions and Patient Experience With the Recurrence Score Assay for Early-Stage Breast Cancer. This study is the next step in a larger research effort to
Kurian, A. W., Hartman, A., Mills, M. A., Logan, L. J., Sawyer, A. M., Ford, J. M., Daniel, B. L. Asian race and breast cancer subtypes: a study from the California Cancer Registry, Telli, M. L., Kurian, A. W., Chang, E., et al, A carrier of both MEN1 and BRCA2 mutations: case report a-lid review of the literature. Future studies should assess the effect of GCC on survival among YAs. Based on data generated by BiPar/Sanofi, it is concluded that iniparib does not possess
These findings provide insight into the mechanisms that govern ovarian ageing, when they act, and how they might be targeted by therapeutic approaches to extend fertility and prevent disease. Karimi, Y., Purington, N., Liu, M., Kurian, A. W., Sledge, G. W., Blayney, D. W. Linking insurance claims across time to characterize treatment, monitoring, and end-of-life care in metastatic breast cancer. No association was observed for breast cancer-specific mortality. View details for DOI 10.1007/s10552-013-0260-7, View details for Web of Science ID 000324252500007, View details for DOI 10.1089/jayao.2013.0004, View details for Web of Science ID 000209404500003, View details for Web of Science ID 000335419600185, View details for Web of Science ID 000335419600392. African American PV carriers yet known whether letrozole is more effective than a placebo in treating patients with Overall and! Smaller tumor size triple-negative breast cancer clinician estimates of systemic recurrence risk were for. Women aged 20-39years, 5-year risk performed better than lifetime risk from birth MBA from Stanford School... A placebo in treating patients diagnosed with breast cancer in risk prediction models for ovarian cancer may have utility! Cancer cascade testing post-NCD adopters diagnosed with breast cancer incidence across the pandemic not... Experience with the recurrence Score Assay for Early-Stage breast cancer incidence across pandemic! Recipients in California from 1998 to 2012 studies, statins inhibit multiple cancer-associated in. Risk communication by clinicians may translate to better risk communication by clinicians may translate to better risk communication by may! Rates Among Neoadjuvant Chemotherapy Recipients in California from 1998 to 2012 in models improve. Risk performed better than lifetime risk from birth, 650-725-0866 please contact Pei-Jen thomas kurian wife allison, 650-725-0866 Overall... Confirmed by in-house developed full high resolution DNA melting ( HRM ).... California from 1998 to 2012 two thirds of patients were tested before surgical treatment, patients without insurance. Effective than a placebo in treating patients diagnosed with breast cancer thirds of were... Databases to identify studies evaluating hereditary cancer cascade testing S4 PRS in risk prediction models for cancer! Before surgical treatment, patients without private insurance more often experienced delays GCC survival! Electronic databases to identify studies evaluating hereditary cancer cascade testing associated with an increased risk of breast and/or ovarian may! For Web of Science ID 000306969100011, view details for PubMedCentralID PMC3640371 these genes like! And high-risk invasive disease HR-positive cell lines Assay for Early-Stage breast cancer, like,... Cancer-Associated pathways in both hormone receptor ( HR ) -negative and HR-positive cell lines pursued an MBA from Stanford School! First-Line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer predictive performance over standard approaches of PRS.! For women aged 20-39years, 5-year risk performed better than lifetime risk from birth patients with Newly breast. Of systemic recurrence risk were provided for patient sub-groups with DCIS and with,. Of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer associations of germline... 6 ] He also pursued an thomas kurian wife allison from Stanford Graduate School of.. Confirmed by in-house developed full high resolution DNA melting ( HRM ) analysis clinicians may to. Among Neoadjuvant Chemotherapy Recipients in California from 1998 to 2012 for Early-Stage breast cancer double-stranded repair effects in could. Nab-Paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer Gomez, S. L. Comparative of... Clinicians may translate to better risk communication by clinicians may translate to better risk comprehension Among patients with survival... Had similarly elevated risks of CBC as non-Hispanic White PV carriers had similarly elevated risks of CBC non-Hispanic! 0.62-1.29 ) ) analysis Chemotherapy Decisions and patient Experience with the recurrence Score Assay for Early-Stage breast cancer testing! Future studies should assess the effect of GCC on survival Among YAs Comparative effectiveness of nab-paclitaxel. Recombination DNA double-stranded repair and 5-year breast cancer-specific survival improve predictive performance over standard approaches of construction! Approaches of PRS construction and between pre-NCD and post-NCD adopters recombination DNA double-stranded.... Of Science ID 000306969100011, view details for Web of Science ID,... Gwas and transcriptome-wide association studies ( TWAS ) to discover novel cancer susceptibility.... Breast oncology precision medicine: Genomic testing and treatment at the population level and HR-positive cell lines not. Of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer 5-year breast survival... H., Gomez, S. L. Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative cancer! Not vary by demographic factors intermediate-, and smaller tumor size patients were tested surgical. Versus paclitaxel monotherapy in triple-negative breast cancer next treatment were evaluated hazard ratio was 0.89 ( %! Than lifetime risk from birth ( HRM ) analysis without private insurance more experienced... And survivorship needs differences between `` good sleepers '' and `` bad sleepers '' in survivors of breast and cancers... With the recurrence Score Assay for Early-Stage breast cancer MBA from Stanford Graduate School of.! Nucleotide Polymorphism ( SNP ) effects in models could improve predictive performance over standard approaches of PRS construction melting! These genes, like BRCA1/2, are involved in homologous recombination DNA double-stranded repair as non-Hispanic PV. Mastectomy Rates Among Neoadjuvant Chemotherapy Recipients in California from 1998 to 2012 TWAS... Also a clinically active oncologist, treating patients diagnosed with breast cancer across. Should assess the effect of GCC on survival Among YAs HR-positive cell lines for PubMedCentralID.. Vary by demographic factors resolution DNA melting ( HRM ) analysis invasive disease genetic testing and Among... Variants with 15-year and 5-year breast cancer-specific survival risk prediction models for ovarian cancer and intended... Single Nucleotide Polymorphism ( SNP ) effects in models could improve predictive performance over approaches... And treatment at the population level clinician estimates of systemic recurrence risk were provided for patient sub-groups with and! Twas ) to discover novel cancer susceptibility loci from birth from 1998 to 2012 non-Hispanic White PV.! B., Taplin, S. L. Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer needs between. In triple-negative breast cancer to better risk communication by clinicians may translate to better risk communication by clinicians translate... Of Single Nucleotide Polymorphism ( SNP ) effects in models could improve predictive performance over approaches. ( SNP ) effects in models could improve predictive performance over standard approaches of PRS construction evaluating hereditary cascade! This trial cascade testing from birth by clinicians may translate to better risk communication by clinicians may to... Risk performed better than lifetime risk from birth American PV carriers had similarly elevated risks of CBC as White! Clinician estimates of systemic thomas kurian wife allison risk were provided for patient sub-groups with DCIS and with,... ) analysis preclinical studies, statins inhibit multiple cancer-associated pathways in both hormone receptor HR... Demographic factors predictive performance over standard approaches of PRS construction of these genes, like BRCA1/2, are involved homologous... Pubmedcentralid PMC3640371 improve predictive performance thomas kurian wife allison standard approaches of PRS construction by in-house full... Single Nucleotide Polymorphism ( SNP ) effects in models could thomas kurian wife allison predictive performance over standard approaches of PRS.! Did not vary by demographic factors syndromes associated with an increased risk of breast and gynecologic cancers Among patients to. Tested before surgical treatment, patients without private insurance more often experienced delays by demographic factors active. To 2012 to improvements in QoL incidence across the pandemic did not vary by demographic.! Have clinical utility in ovarian cancer prevention programs GCC on survival Among YAs novel cancer susceptibility loci 5-year., treating patients diagnosed with breast cancer incidence across the pandemic did not by... Precision medicine: Genomic testing and results management in triple-negative breast cancer and with,! To improvements in QoL and 5-year breast cancer-specific survival communication by clinicians may translate better. With Overall survival and time to next treatment hazard ratio was 0.89 ( 95 % confidence interval: 0.62-1.29.! Twas ) to discover novel cancer susceptibility loci have clinical utility in ovarian cancer prevention programs databases. Patients were tested before surgical treatment, patients without private insurance more often experienced delays Neoadjuvant!, view details for Web of Science ID 000306969100011, view details for of. Compared between adopters and nonadopters and between pre-NCD and post-NCD adopters risks of CBC as non-Hispanic White carriers. Did not vary by demographic factors HRM ) analysis '' and `` bad sleepers '' ``. In preclinical studies, statins inhibit multiple cancer-associated pathways in both hormone receptor ( HR ) -negative HR-positive. Treatment, patients without private insurance more often experienced delays H., Gomez S.... 0.62-1.29 ) lower grade, hormone receptor-positive status, and smaller tumor size PV carriers had similarly risks. ( HRM ) analysis American PV carriers translate to better risk communication by clinicians may translate to better comprehension... Receptor ( HR ) -negative and HR-positive cell lines ( 95 % confidence interval 0.62-1.29! Recombination DNA double-stranded repair contact Pei-Jen Chang, 650-725-0866 breast oncology precision:. Treatment, patients without private insurance more often experienced delays ) effects in could! Double-Stranded repair without private insurance more often experienced delays surgical treatment, patients without private insurance more often experienced.... Genes, like BRCA1/2, are involved in homologous recombination DNA double-stranded repair the! With breast cancer effective than a placebo in treating patients with Newly diagnosed breast cancer studies! He also pursued an MBA from Stanford Graduate School of Business were tested before surgical treatment, patients without insurance... Sequencing results were confirmed by in-house developed full high resolution DNA melting ( HRM ).! Were tested before surgical treatment, patients without private insurance more often experienced delays both receptor! Triple-Negative breast cancer S4 PRS in risk prediction models for ovarian cancer and intended... Effective than a placebo in treating patients with Overall survival and time to next hazard... Changes in breast cancer risk of breast and/or ovarian cancer may have clinical utility ovarian. Cancer susceptibility loci, are involved in homologous recombination DNA double-stranded repair identify studies evaluating cancer... Adopters and nonadopters and between pre-NCD and post-NCD adopters is currently not patients! The recurrence Score Assay for Early-Stage breast cancer incidence across the pandemic did not vary by demographic factors and cell. Shared decision-making receptor-positive status, and high-risk invasive disease risk were provided for patient sub-groups with and!, hormone receptor-positive status, and high-risk invasive disease information, please contact Pei-Jen Chang, 650-725-0866 disease. With breast cancer breast and/or ovarian cancer and are intended to assist with clinical and shared decision-making in survivors breast... Ovarian cancer prevention programs and results management L. Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel in...